@article { author = {}, title = {Pemetrexed is Mildly Active with Good Tolerability for Treatment of Patients with Colorectal Cancer}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {15}, number = {19}, pages = {8391-8394}, year = {2014}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {Purpose: This systematic analysis was conducted to evaluate the efficacy and safety of pemetrexed basedsalvage chemotherapy for treatment of patients with metastatic colorectal cancer. Methods: Clinical studiesevaluating the efficacy and safety of pemetrexed based regimens on response and safety for patients with colorectalcancer were identified using a predefined search strategy. Pooled response rates (RRs) were calculated. Results:For pemetrexed based regimens, 4 clinical studies including 201 patients with advanced colorectal cancer wereconsidered eligible for inclusion. The analysis suggested that, in all patients, pooled RR was 20.4% (41/201).Major adverse effects were neutropenia, anorexia, fatigue, and anemia. No treatment related death occurredwith pemetrexed based treatment. Conclusion: This systematic analysis suggests that pemetrexed based regimensare associated with mild activity with good tolerability in treating patients with metastatic colorectal cancer.}, keywords = {metastatic colorectal cancer,pemetrexed chemotherapy,response rate}, url = {https://journal.waocp.org/article_29930.html}, eprint = {https://journal.waocp.org/article_29930_4a262a9518aaf8f0cb6dd78647b24bb5.pdf} }